What is HC Wainwright’s Forecast for STOK Q3 Earnings?

Stoke Therapeutics, Inc. (NASDAQ:STOK) – Stock analysts at HC Wainwright issued their Q3 2025 EPS estimates for shares of Stoke Therapeutics in a report issued on Wednesday, March 19th. HC Wainwright analyst A. Fein forecasts that the company will post earnings per share of ($0.55) for the quarter. HC Wainwright currently has a “Buy” rating and a $47.00 target price on the stock. The consensus estimate for Stoke Therapeutics’ current full-year earnings is ($2.01) per share. HC Wainwright also issued estimates for Stoke Therapeutics’ Q4 2025 earnings at ($0.56) EPS, FY2025 earnings at ($2.18) EPS, FY2026 earnings at ($2.87) EPS, FY2027 earnings at ($2.06) EPS, FY2028 earnings at ($1.21) EPS and FY2029 earnings at $0.22 EPS.

Stoke Therapeutics (NASDAQ:STOK) last issued its quarterly earnings data on Monday, March 24th. The company reported ($0.18) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.38. Stoke Therapeutics had a negative net margin of 629.90% and a negative return on equity of 54.45%. The firm had revenue of $22.61 million during the quarter, compared to the consensus estimate of $4.20 million.

STOK has been the subject of a number of other research reports. Needham & Company LLC reissued a “buy” rating and issued a $22.00 target price on shares of Stoke Therapeutics in a research report on Tuesday. Cantor Fitzgerald reissued an “overweight” rating on shares of Stoke Therapeutics in a report on Tuesday, December 10th. Finally, Chardan Capital reaffirmed a “buy” rating and set a $24.00 target price on shares of Stoke Therapeutics in a report on Wednesday. One research analyst has rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average target price of $23.00.

Stoke Therapeutics Price Performance

STOK opened at $8.33 on Friday. The business has a fifty day simple moving average of $9.49 and a 200 day simple moving average of $11.49. Stoke Therapeutics has a 1 year low of $5.80 and a 1 year high of $17.58. The company has a market capitalization of $441.22 million, a PE ratio of -3.97 and a beta of 0.99.

Hedge Funds Weigh In On Stoke Therapeutics

A number of institutional investors have recently added to or reduced their stakes in STOK. KLP Kapitalforvaltning AS acquired a new stake in Stoke Therapeutics in the fourth quarter valued at approximately $63,000. Teacher Retirement System of Texas bought a new stake in Stoke Therapeutics during the 4th quarter worth $113,000. China Universal Asset Management Co. Ltd. acquired a new position in Stoke Therapeutics in the 4th quarter worth about $124,000. Tower Research Capital LLC TRC increased its holdings in Stoke Therapeutics by 70.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 11,930 shares of the company’s stock worth $132,000 after purchasing an additional 4,918 shares in the last quarter. Finally, Invesco Ltd. acquired a new stake in shares of Stoke Therapeutics during the fourth quarter valued at about $133,000.

Insider Activity at Stoke Therapeutics

In other news, Director Edward M. Md Kaye sold 10,382 shares of Stoke Therapeutics stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $90,011.94. Following the transaction, the director now owns 148,253 shares in the company, valued at approximately $1,285,353.51. This trade represents a 6.54 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Barry Ticho sold 3,884 shares of the company’s stock in a transaction on Tuesday, March 18th. The stock was sold at an average price of $8.67, for a total value of $33,674.28. Following the sale, the insider now owns 63,962 shares of the company’s stock, valued at approximately $554,550.54. This represents a 5.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 16,532 shares of company stock valued at $143,332 over the last three months. 11.30% of the stock is owned by insiders.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.